Neurizon Therapeutics (ASX: NUZ) has announced encouraging outcomes from an independent study assessing its neuroprotective ...

Neurizon Therapeutics Ltd (ASX:NUZ) has yielded positive results from an independent study – conducted in collaboration with ...

NUZ-001 has shown it promotes healthy and viable brain tissues, potentially demonstrating its use to treat Alzheimer’s and ...

Neurizon Therapeutics' (ASX:NUZ) lead drug candidate has demonstrated positive results in the latest round of testing with ...

Several ASX healthcare companies are leading the charge in finding new treatments for complex neurological disorders.

NUZ-001 slowed respiratory declines in ALS patients in a Phase 1 trial, and Neurizon is working to ready it for the HEALEY ...

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Neurizon Therapeutics Limited (NUZ). However, you won't necessarily see their names in the ...

In this episode, Tylah Tully gives the skinny on Neurizon Therapeutics (ASX:NUZ) HEALEY ALS Platform Trial, as the company ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Neurizon Therapeutics (ASX: NUZ) announced last month that the regulator had requested additional animal exposure data be provided to assess adequacy of systemic exposure to NUZ-001 during the ...

Neurizon Therapeutics plans to implement several initiatives to get the clinical hold lifted of its IND application for NUZ-001. The company has been in discussion with the US FDA since February ...